- Double-blinding.
- Triple-blinding.
- Single-blinding.
- Open-label.
No category found.
- Information bias.
- Selection bias.
- Observer bias.
- Confounding.
- Pre-clinical.
- Phase I.
- Phase II.
- Phase III.
- Endemic.
- Epidemic.
- Pandemic.
- Sporadic.
- Wait for a definitive diagnosis before informing anyone.
- Immediately isolate the patient, collect samples, and notify the local infectious disease control unit.
- Treat symptomatically and discharge.
- Refer to a general practitioner for routine follow-up.
- Many false positive results.
- Many false negative results, potentially leading to missed diagnoses.
- Accurate diagnosis immediately.
- No need for further testing.
- Relative Risk.
- Odds Ratio.
- Absolute Risk Reduction (ARR).
- Number Needed to Harm (NNH).
- Bias.
- Random error.
- Confounder.
- Effect modifier.
- Advise people to boil water before use.
- Issue an immediate "boil water" advisory, identify affected areas, and coordinate with healthcare providers for case management.
- Wait for lab confirmation from every affected individual.
- Only provide bottled water to a few households.
- Sensitivity.
- Specificity.
- Lead-time bias.
- Prognostic benefit of early detection.
- The association is highly plausible.
- The association needs to be critically examined for biological plausibility; rare exposure causing common disease is less common.
- Biological plausibility is irrelevant.
- The chemical is definitely carcinogenic.
- Scatter plot.
- Bar chart.
- Epidemic curve.
- Pie chart.
- Provide more naloxone to paramedics only.
- Implement immediate harm reduction strategies, distribute naloxone, and investigate the source of contaminated drugs.
- Wait for the increase to plateau.
- Blame the individuals for drug use.
- Prevalence of infections.
- Incidence rate of new infections.
- Mortality rate from infections.
- Case-fatality rate from infections.
- Recall bias.
- Information bias.
- Selection bias.
- Observer bias.
- No special monitoring is needed.
- Very close and ongoing monitoring of patients for adverse effects and therapeutic levels is required.
- The drug is too dangerous to be approved.
- The drug is extremely safe.
- Reservoir.
- Host.
- Agent.
- Susceptible population.
